Weiskirchen R - Search Results

1

CCN proteins in normal and injured liver.

Weiskirchen R. Weiskirchen R. Front Biosci (Landmark Ed). 2011 Jan 1;16(5):1939-61. doi: 10.2741/3832. Front Biosci (Landmark Ed). 2011. PMID: 21196275 Review.

2

LIM-domain protein cysteine- and glycine-rich protein 2 (CRP2) is a novel marker of hepatic stellate cells and binding partner of the protein inhibitor of activated STAT1.

Weiskirchen R, Moser M, Weiskirchen S, Erdel M, Dahmen S, Buettner R, Gressner AM. Weiskirchen R, et al. Among authors: weiskirchen s. Biochem J. 2001 Nov 1;359(Pt 3):485-96. doi: 10.1042/0264-6021:3590485. Biochem J. 2001. PMID: 11672422 Free PMC article.

3

Roles of TGF-beta in hepatic fibrosis.

Gressner AM, Weiskirchen R, Breitkopf K, Dooley S. Gressner AM, et al. Among authors: weiskirchen r. Front Biosci. 2002 Apr 1;7:d793-807. doi: 10.2741/A812. Front Biosci. 2002. PMID: 11897555 Review.

4

Adenoviral delivery of an antisense RNA complementary to the 3' coding sequence of transforming growth factor-beta1 inhibits fibrogenic activities of hepatic stellate cells.

Arias M, Lahme B, Van de Leur E, Gressner AM, Weiskirchen R. Arias M, et al. Among authors: weiskirchen r. Cell Growth Differ. 2002 Jun;13(6):265-73. Cell Growth Differ. 2002. PMID: 12114216

5

The CRP/MLP/TLP family of LIM domain proteins: acting by connecting.

Weiskirchen R, Günther K. Weiskirchen R, et al. Bioessays. 2003 Feb;25(2):152-62. doi: 10.1002/bies.10226. Bioessays. 2003. PMID: 12539241 Review.

6

Adenoviral expression of a transforming growth factor-beta1 antisense mRNA is effective in preventing liver fibrosis in bile-duct ligated rats.

Arias M, Sauer-Lehnen S, Treptau J, Janoschek N, Theuerkauf I, Buettner R, Gressner AM, Weiskirchen R. Arias M, et al. Among authors: weiskirchen r. BMC Gastroenterol. 2003 Oct 18;3:29. doi: 10.1186/1471-230X-3-29. BMC Gastroenterol. 2003. PMID: 14565855 Free PMC article.

7

Analysis of the transforming growth factor-beta1 (TGF-beta1) codon 25 gene polymorphism by LightCycler-analysis in patients with chronic hepatitis C infection.

Tag CG, Mengsteab S, Hellerbrand C, Lammert F, Gressner AM, Weiskirchen R. Tag CG, et al. Among authors: weiskirchen r. Cytokine. 2003 Dec 7;24(5):173-81. doi: 10.1016/j.cyto.2003.08.007. Cytokine. 2003. PMID: 14596813

8

Inhibitory effect of soluble PDGF-beta receptor in culture-activated hepatic stellate cells.

Borkham-Kamphorst E, Stoll D, Gressner AM, Weiskirchen R. Borkham-Kamphorst E, et al. Among authors: weiskirchen r. Biochem Biophys Res Commun. 2004 Apr 30;317(2):451-62. doi: 10.1016/j.bbrc.2004.03.064. Biochem Biophys Res Commun. 2004. PMID: 15063779

9

Dominant-negative soluble PDGF-beta receptor inhibits hepatic stellate cell activation and attenuates liver fibrosis.

Borkham-Kamphorst E, Herrmann J, Stoll D, Treptau J, Gressner AM, Weiskirchen R. Borkham-Kamphorst E, et al. Among authors: weiskirchen r. Lab Invest. 2004 Jun;84(6):766-77. doi: 10.1038/labinvest.3700094. Lab Invest. 2004. PMID: 15077122

10

CSRP2, TIMP-1, and SM22alpha promoter fragments direct hepatic stellate cell-specific transgene expression in vitro, but not in vivo.

Herrmann J, Arias M, Van De Leur E, Gressner AM, Weiskirchen R. Herrmann J, et al. Among authors: weiskirchen r. Liver Int. 2004 Feb;24(1):69-79. doi: 10.1111/j.1478-3231.2004.00891.x. Liver Int. 2004. PMID: 15102003

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results